https://www.nasdaq.com/press-release/avadel-pharmaceuticals-to-present-at-upcoming-investor-conferences-2021-11-22
https://www.nasdaq.com/press-release/avadel-pharmaceuticals-to-present-at-upcoming-investor-conferences-in-november-2021
https://www.nasdaq.com/press-release/avadel-pharmaceuticals-provides-corporate-update-and-reports-third-quarter-2021
https://www.nasdaq.com/press-release/avadel-pharmaceuticals-to-provide-a-corporate-update-and-report-third-quarter-2021
https://www.nasdaq.com/press-release/avadel-presents-new-data-supporting-clinical-benefit-with-once-at-bedtime-ft218-and
https://www.nasdaq.com/press-release/avadel-pharmaceuticals-announces-ongoing-fda-review-of-nda-for-ft218-for-patients
https://www.nasdaq.com/press-release/avadel-recognizes-world-narcolepsy-day-and-announces-new-data-presentations-from
https://www.nasdaq.com/press-release/avadel-pharmaceuticals-to-present-at-upcoming-investor-conferences-2021-09-02
https://www.nasdaq.com/press-release/avadel-pharmaceuticals-announces-publication-of-data-from-pivotal-phase-3-rest-on
https://www.nasdaq.com/press-release/avadel-pharmaceuticals-provides-corporate-update-and-reports-second-quarter-2021
https://www.nasdaq.com/press-release/avadel-pharmaceuticals-to-provide-a-corporate-update-and-report-second-quarter-2021
https://www.nasdaq.com/press-release/avadel-pharmaceuticals-to-present-at-the-ladenburg-thalmann-annual-healthcare
https://www.nasdaq.com/press-release/avadel-presents-new-clinical-data-from-pivotal-phase-3-rest-on-trial-supporting
https://www.nasdaq.com/press-release/avadel-to-present-new-efficacy-and-safety-data-from-pivotal-phase-3-rest-on-trial-of
https://www.nasdaq.com/press-release/avadel-pharmaceuticals-expands-leadership-team-with-three-strategic-hires-2021-06-02
https://www.nasdaq.com/press-release/avadel-pharmaceuticals-to-present-at-the-jefferies-virtual-healthcare-conference-2021
https://www.nasdaq.com/press-release/avadel-pharmaceuticals-provides-corporate-update-and-reports-first-quarter-2021
https://www.nasdaq.com/press-release/avadel-pharmaceuticals-to-provide-a-corporate-update-and-report-first-quarter-2021
https://www.nasdaq.com/press-release/avadel-presents-new-data-from-its-pivotal-rest-on-phase-3-trial-of-ft218-once-nightly
https://www.nasdaq.com/press-release/avadel-to-present-new-data-from-its-pivotal-rest-on-phase-3-study-of-ft218-at-the
https://www.nasdaq.com/press-release/avadel-pharmaceuticals-to-participate-in-a-fireside-chat-at-stifels-third-annual-cns
https://www.nasdaq.com/press-release/avadel-pharmaceuticals-provides-corporate-update-and-reports-fourth-quarter-and-full
https://www.nasdaq.com/press-release/avadel-pharmaceuticals-and-the-american-academy-of-sleep-medicine-foundation-announce
https://www.nasdaq.com/press-release/avadel-pharmaceuticals-announces-publication-of-once-nightly-ft218-pharmacokinetic
https://www.nasdaq.com/press-release/avadel-pharmaceuticals-announces-fda-acceptance-of-new-drug-application-for-ft218-in
https://www.nasdaq.com/press-release/avadel-pharmaceuticals-to-participate-in-fireside-chats-at-upcoming-march-2021
https://www.nasdaq.com/press-release/avadel-pharmaceuticals-to-provide-a-company-update-and-report-fourth-quarter-and-full
https://www.nasdaq.com/press-release/avadel-pharmaceuticals-appoints-richard-kim-as-chief-commercial-officer-to-lead-the
https://www.nasdaq.com/press-release/avadel-pharmaceuticals-to-participate-in-a-fireside-chat-at-the-10th-annual-svb
https://www.nasdaq.com/press-release/avadel-pharmaceuticals-announces-submission-of-new-drug-application-for-ft218-to-the
https://www.nasdaq.com/press-release/avadel-pharmaceuticals-added-to-nasdaq-biotechnology-index-2020-12-15
https://www.nasdaq.com/press-release/avadel-pharmaceuticals-appoints-dr.-jennifer-gudeman-as-vice-president-of-medical-and
https://www.nasdaq.com/press-release/avadel-pharmaceuticals-to-present-at-upcoming-december-2020-investor-conferences-2020
https://www.nasdaq.com/press-release/avadel-pharmaceuticals-to-present-at-upcoming-november-2020-investor-conferences-2020
https://www.nasdaq.com/press-release/avadel-pharmaceuticals-reports-third-quarter-2020-financial-results-and-provides
https://www.nasdaq.com/press-release/avadel-pharmaceuticals-to-report-third-quarter-2020-financial-results-on-november-9th
https://www.nasdaq.com/press-release/avadel-to-present-at-the-oppenheimer-fall-healthcare-life-sciences-medtech-summit
https://www.nasdaq.com/press-release/avadel-pharmaceuticals-announces-ft218-leadership-transition-2020-09-14
https://www.nasdaq.com/press-release/avadel-to-present-at-h.c.-wainwright-22nd-annual-global-investment-conference-2020-09
https://www.nasdaq.com/press-release/avadel-pharmaceuticals-reports-second-quarter-2020-financial-results-and-recent
https://www.nasdaq.com/press-release/avadel-pharmaceuticals-to-report-second-quarter-2020-financial-results-on-august-10th
https://www.nasdaq.com/press-release/avadel-pharmaceuticals-announces-first-patient-dosed-in-open-label-extension-switch
https://www.nasdaq.com/press-release/avadel-announces-sale-of-hospital-sterile-injectable-drug-portfolio-for-%2442.0-million
https://www.nasdaq.com/press-release/avadel-pharmaceuticals-to-present-at-bio-digital-2020-06-08
https://www.nasdaq.com/press-release/avadel-pharmaceuticals-to-present-at-jefferies-virtual-healthcare-conference-2020-06
https://www.nasdaq.com/press-release/avadel-pharmaceuticals-reports-first-quarter-2020-financial-results-2020-05-11
https://www.nasdaq.com/press-release/avadel-pharmaceuticals-to-report-first-quarter-2020-financial-results-on-may-11th
https://www.nasdaq.com/press-release/avadel-pharmaceuticals-announces-pricing-of-public-offering-2020-04-28
https://www.nasdaq.com/press-release/avadel-pharmaceuticals-announces-proposed-underwritten-public-offering-2020-04-27
https://www.nasdaq.com/press-release/avadel-pharmaceuticals-announces-positive-topline-results-from-its-pivotal-phase-3
https://www.nasdaq.com/press-release/avadel-pharmaceuticals-completes-the-rest-on-phase-3-pivotal-trial-of-ft218-for
https://www.nasdaq.com/press-release/avadel-pharmaceuticals-reports-fourth-quarter-and-full-year-2019-financial-results
https://www.nasdaq.com/press-release/avadel-pharmaceuticals-to-report-fourth-quarter-and-year-end-2019-financial-results
https://www.nasdaq.com/press-release/avadel-pharmaceuticals-announces-%2465-million-private-placement-with-leading-biotech
https://www.nasdaq.com/press-release/longuevue-capital-adds-experienced-healthcare-operating-partners-to-support-new
https://www.nasdaq.com/press-release/avadel-pharmaceuticals-completes-enrollment-in-the-rest-on-phase-3-pivotal-trial-of
https://www.nasdaq.com/press-release/avadel-pharmaceuticals-receives-u.s.-fda-approval-for-nouresstm-av001-a-cysteine
https://www.nasdaq.com/press-release/avadel-pharmaceuticals-appoints-dr.-mark-mccamish-to-its-board-of-directors-2019-12
https://www.nasdaq.com/press-release/avadel-pharmaceuticals-announces-key-appointments-to-leadership-team-to-support
https://www.nasdaq.com/press-release/avadel-pharmaceuticals-achieves-enrollment-target-in-rest-on-phase-3-pivotal-trial-of
https://www.nasdaq.com/press-release/avadel-pharmaceuticals-to-present-at-two-upcoming-investor-conferences-2019-11-21
https://www.nasdaq.com/press-release/avadel-pharmaceuticals-reports-third-quarter-2019-financial-results-and-raises
https://www.nasdaq.com/press-release/avadel-pharmaceuticals-to-report-third-quarter-2019-financial-results-on-november
https://www.nasdaq.com/press-release/avadel-announces-resignation-of-kevin-kotler-from-board-of-directors-2019-10-04
